Guangzhou Wondfo Biotech (300482.SZ) releases the results of the private placement, with many renowned investment institutions rushing to subscribe.

On the evening of March 14th, Guangzhou Wondfo Biotech (300482.SZ), a leading POCT company, disclosed a report on the issuance of shares to specific objects, announcing the successful completion of this private placement. The company issued a total of 27.45 million shares to specific objects at a price of 25.50 yuan per share, raising approximately 700 million yuan. The report shows that a total of 53 subscription objects participated in the bidding, with many high-quality investment institutions participating, including state-owned investment platforms, insurance institutions, public institutions, private equity funds, top brokerage firms, asset management institutions, etc. The investors showed strong willingness to subscribe and received multiple times the subscriptions. A total of 17 professional investors were finally allocated shares in this private placement, with Guangdong Hengkuo Investment Management Co., Ltd. (referred to as "Guangdong Hengkuo") being the largest investor, with an allocation of approximately 150 million yuan. It is worth mentioning that Guangdong Hengjian Investment Holding Company (referred to as "Hengjian Holding") is the only provincial-level state-owned capital operation company and industry-finance integration platform in Guangdong Province. Guangdong Hengkuo is a wholly-owned subsidiary of Hengjian Holding, with the mission of injecting new energy into state-owned capital operation, supporting industrial upgrading and economic and social development in Guangdong, and promoting the rapid development of the Guangdong-Hong Kong-Macau Greater Bay Area. Two insurance institutions appeared on the list of recipients, with 5 products under Huatai Fund Management receiving a total allocation of approximately 110 million yuan, and 2 products under Taikang Fund Management receiving a total of approximately 85 million yuan. In addition, Caitong Fund and Nord Fund received allocations of 88.9 million yuan and 60.7 million yuan respectively, both of which are well-known public funds. Head brokerage firms such as Guotai Junan, Guotai Junan Fund Management, CITIC SEC Fund Management, etc., participated, with a total allocation exceeding 70 million yuan. Guangzhou Wondfo Biotech specializes in the research and development, production, marketing, and service of POCT rapid diagnostic reagents and supporting instruments. It is one of the leading domestic companies in the POCT industry and the leading medical device company in Guangdong. The company attaches great importance to the innovation and iterative upgrading of in vitro diagnostic products. After more than 30 years of deep cultivation and a high proportion of research and development investment, it has expanded from the initial immunocolloid gold and immunofluorescence technology platform to nine major technology platforms such as chemiluminescence and molecular diagnostics. It continues to promote industry development with scientific research innovation, becoming the domestic POCT company with the most technology platforms and the most abundant product line. The announcement shows that the funds raised will be mainly used for the construction of the Knowledge City production base project, the biological raw material research and development project, etc., focusing on upgrading production capacity with intelligent factories and extending upstream into the in vitro diagnostic industry chain to secure a high-profit margin in the biological raw material link, improve supply chain security, and continuously optimize the company's capital and business structure. Industry insiders analyze that after upgrading its own production capacity and connecting the business link of independent research and production of biological raw materials, Guangzhou Wondfo Biotech will form an integrated layout of raw materials, reagents, and instruments. The implementation of the private placement project will help Guangzhou Wondfo Biotech further expand its business scale, enhance the competitiveness of the company in the market, increase its market share and industry position, and steadily move towards becoming a globally influential IVD company.